Patheon NV (NASDAQ: PTHN) and Pacira Pharmaceuticals (NASDAQ:PCRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitabiliy, risk and analyst recommendations.

Valuation & Earnings

This table compares Patheon NV and Pacira Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Patheon NV $1.93 billion 2.63 $352.50 million N/A N/A
Pacira Pharmaceuticals $281.47 million 5.16 -$34.94 million ($1.71) -21.17

Patheon NV has higher revenue and earnings than Pacira Pharmaceuticals.

Profitability

This table compares Patheon NV and Pacira Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Patheon NV 5.71% N/A 4.09%
Pacira Pharmaceuticals -23.36% -12.44% -6.07%

Analyst Recommendations

This is a summary of current recommendations for Patheon NV and Pacira Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Patheon NV 0 7 4 0 2.36
Pacira Pharmaceuticals 1 5 8 0 2.50

Patheon NV currently has a consensus price target of $32.45, suggesting a potential downside of 7.21%. Pacira Pharmaceuticals has a consensus price target of $55.18, suggesting a potential upside of 52.44%. Given Pacira Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Pacira Pharmaceuticals is more favorable than Patheon NV.

Summary

Patheon NV beats Pacira Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Patheon NV Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with Analyst Ratings Network's FREE daily email newsletter.